To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Bioventus is at a significant inflection point, focusing on four powerful growth drivers while aiming to enhance profitability, increase cash flow, and drive shareholder value [3]. Company Overview - Bioventus' mission is to assist patients in recovering and living life to the fullest [2]. - The company has undergone significant changes and demonstrated strong performance over the past few years [3]. Growth Strategy - The company is concentrating on igniting four key growth drivers to propel its future success [3]. - There is an emphasis on expanding profitability and increasing cash flow alongside growth initiatives [3].

Bioventus Conference Call Summary Company Overview - **Company**: Bioventus - **Industry**: Healthcare, specifically in pain treatments, surgical solutions, and restorative therapies - **Annual Revenue**: Over $550 million - **Market Opportunity**: Over $6 billion across its portfolio [3][4] Core Business and Growth Drivers - **Core Business**: Comprises HA, bone graft substitutes, and fracture care, generating significant cash flow and high margins [6] - **Expansion Platform**: Includes ultrasonics and international markets, expected to contribute significantly to revenue growth [6][12] - **Emerging Growth Platform**: Focuses on peripheral nerve stimulation (PNS) and platelet-rich plasma (PRP), with PNS projected to grow at around 24% and PRP over 10% [7][9] - **Revenue Contribution**: By 2026, PNS and PRP are expected to contribute 200 basis points of growth [10] Financial Performance - **Gross Margin**: Peer-leading gross margin in the mid-70s% [15] - **EBITDA Margin**: Expanded by roughly 700 basis points [4] - **Operating Cash Flow**: Over $100 million generated in the last two years, with expectations for cash flow to double in 2025 [5][34] - **Debt Reduction**: Debt reduced to below $300 million, with a leverage ratio below 2.5 times [16] Strategic Initiatives - **Investment Focus**: Disproportionate investment in expansion and emerging platforms, including PNS sales organization and international sales resources [13][14] - **International Expansion**: Targeting EMEA and APAC regions with a disciplined approach to market entry [29][30] - **M&A Strategy**: High bar for M&A, focusing on synergistic opportunities that meet strong financial metrics [17][32] Market Position and Competition - **PNS Technology**: Unique advantages include being the only technology designed for peripheral nerves, with a full launch expected soon [8][22] - **Ultrasonics**: Aiming to establish this technology as the standard of care in spinal surgery through education and marketing [25][26] - **PRP Market**: Positioned to leverage existing HA salesforce, emphasizing customization and efficiency in treatment [9][27] Macroeconomic Considerations - **Tariff and FX Headwinds**: Anticipated $1-$2 million in tariffs for 2026, with a proactive management approach to overcome these challenges [35][36] Conclusion - **Future Outlook**: Bioventus is positioned for significant growth with a strong foundation, focusing on expanding its portfolio and enhancing profitability while managing financial discipline [18]

Core Viewpoint - Bioventus Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its innovations in active healing [1] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [2] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [2] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [2]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Bioventus Inc. which may affect shareholder rights [1] Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Bioventus may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Viewpoint - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues, particularly when ad-blockers are enabled [1] Group 1 - The article suggests that users may face restrictions if they have ad-blockers enabled, indicating a need for adjustments in browser settings to ensure smooth access [1]

Summary of Bioventus Conference Call Company Overview - **Company**: Bioventus - **Industry**: Medical Technology (Med Tech) - **Annual Revenue**: Over $550 million - **Market Opportunity**: $6 billion across product categories [4][5] Core Business Segments - **Business Segments**: - Pain Treatment - Surgical Solutions - Restorative Therapies - **Market Position**: Category or growth leader in all segments [4] Financial Performance - **Growth Rate**: Expected to grow nearly 2X the weighted average market growth rate despite unfavorable comparisons in the first half of the year [5] - **EBITDA Margin**: Guidance for the year is just over 20%, representing a 100 basis points improvement from the previous year [6] - **Cash Flow Improvement**: Significant progress with cash flow expected to nearly double this year, driven by higher EBITDA, lower interest expenses, and efficient working capital [17][18] Growth Drivers Core Growth Drivers - **Hyaluronic Acid (HA) Therapy**: - Focused on knee osteoarthritis pain with Durolane as a leading product - Strong clinical differentiation and largest dedicated sales force in the space [7][8] - **Bone Graft Substitutes (BGS)**: - Focused on spinal surgery with high single-digit growth [8] - **Fracture Care**: - Restored to growth with double-digit growth in recent quarters, expecting mid-single-digit growth moving forward [9] Expansion Growth Drivers - **Ultrasonics Technology**: - Aimed at changing the standard of care for bone cutting in spine surgery, expected to drive significant growth [10][11] - **International Segment**: - New leadership and plans to aggressively pursue international opportunities, expecting double-digit growth [11] Emerging Growth Drivers - **Peripheral Nerve Stimulation (PNS)**: - Current market size of $200 million in the U.S., expected to exceed $500 million by 2029 [12] - Introduction of StimTrial and Talisman PNS system to enhance treatment options [13] - **Platelet-Rich Plasma (PRP)**: - Current market size of $400 million in the U.S., growing in high single digits, with exclusive distribution agreement for Excel PRP system [14] Strategic Focus - **Value Creation**: - Combination of above-market growth and peer-leading gross margin allows for margin expansion while investing in future growth drivers [16][20] - **Cash Flow and Debt Management**: - Expected leverage to drop below 2.5x, providing optionality for capital deployment [18][19] Conclusion - **Future Outlook**: - Bioventus aims to become a $1 billion high-growth, high-profit, high-cash flow company focused on patient recovery and quality of life [20]

Financial Performance & Growth - The company reported Last Twelve Months (LTM) global proforma revenue of $564 million[7] - The company is experiencing above-market revenue growth, with eight quarters of mid-single-digit or higher growth[8] - The company's organic growth is projected at 7% in 2025[12] - The company's Adjusted EBITDA margin is expected to increase from 13.4% in 2022 to 20.2% in 2025[14] - Cash from Operations is projected to nearly double from 2024 to 2025[19] Market & Strategy - The company operates in a $6.4 billion addressable market[7] - The company has a diversified portfolio in large and growing markets, including Pain Treatments, Surgical Solutions, and Restorative Therapies[8, 6] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[8, 24] - The company aims to increase EBITDA and cash flow to continue reducing leverage[8] Future Outlook - The company projects a net leverage ratio of less than 2.5x by the end of 2025[27] - The company anticipates a free cash flow yield of approximately 60% in 2025[27]

Group 1 - The article discusses the active deal-making environment for Bioventus (BVS) in 2022, highlighting the various moving parts that investors are evaluating for value [1] - The service "Value in Corporate Events" offers insights into major corporate events such as earnings reports, M&A, and IPOs, aiming to identify actionable investment opportunities [1] - The investing group provides coverage of approximately 10 major events each month, focusing on finding the best opportunities for its members [1]

Core Points - Bioventus Inc. will present at the Piper Sandler Healthcare Conference on December 3, 2025, at 10:10 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]